Exelixis, Inc. (EXEL) Fundamental Checkup
Exelixis, Inc. fundamental checkup using revenue growth, EPS growth, free cash flow, margins, ROIC, debt-to-equity, and TGMCharts chart exhibits as of August 28, 2026.
By TGMCharts Research · Data as of · Updated
Exelixis, Inc. gets a balanced fundamental read when revenue growth of 16.06%, EPS growth of 51.51%, free-cash-flow growth of 40.17%, net margin of 35.33%, and ROIC of 37.87% support the same story.
The checkup weighs operating growth, shareholder conversion, cash conversion, reinvestment quality, and balance-sheet flexibility. Current ratio is 3.46x and debt-to-equity is 0.09x, so the balance-sheet read is part of the final view rather than a footnote.
- Exelixis, Inc. has market cap of $13.73B and closed at $54.45 on August 28, 2026.
- Five-year revenue CAGR is 16.06% and five-year EPS CAGR is 51.51%.
- Five-year free-cash-flow CAGR is 40.17%.
- Net margin is 35.33% and ROIC is 37.87%.
- Current ratio is 3.46x and debt-to-equity is 0.09x.
Fundamental snapshot
The valuation, growth, profitability, and balance-sheet facts behind the checkup.
Core Operational Alignment and Value Creation
Evaluating Exelixis, Inc. requires an integrated examination of its expanding top-line trajectory, underlying cash generation, structural profitability, and balance sheet strength. At the current market price of $54.45 as of August 28, 2026, the central analytical task is to determine if these operational dimensions present a unified picture of financial health. Rather than isolating a single positive or negative metric, this checkup maps out how robustly the core business supports the current market capitalization.
The long-term expansion of the firm is highlighted by a five-year revenue compound annual growth rate of 16.06% alongside a five-year EPS CAGR of 51.51%. When cross-referenced with a five-year free-cash-flow CAGR of 40.17%, we can assess whether the reported bottom-line expansion is backed by real cash generation or if it is merely an accounting artifact. A thorough review of these trends provides the necessary foundation for understanding the company's intrinsic performance.
Current compounder snapshot · EXEL
Live supporting context; not part of the article's frozen 2026-08-28 evidence snapshot.
- Score
- 24/100
- 10Y CAGR
- 51.1%
- Median YoY
- 18.6%
- YoY volatility
- σ 146.1pp· choppy
- Quarters ≥ 20%
- 19 of 40
- Negative quarters
- 3
- Valuation vs own 10Y history
- P/S 5.8x · 10Y median 5.7x · 53rd percentile · as of Aug 31, 2026
How this score is computed
- Quarters at or above 20%: 19 of 40 → 19 of 40 pts
- Steadiness (typical swing 146.1pp) → 0 of 25 pts
- Pace (median 18.6% YoY) → 4.8 of 20 pts
- Latest quarter (10.6% YoY) → 0 of 15 pts
- Score: 24 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
A Unified Perspective on Healthcare Operations
As an active participant in the Healthcare sector, the company must be analyzed through its concrete operating history. This snapshot synthesizes core growth rates, capital efficiency metrics, and balance sheet liquidity indicators to establish a baseline of operational quality. By reviewing these variables in tandem, analysts can evaluate the stability of the enterprise before examining individual financial statements and historical trends.
Fundamental evidence table
A compact cross-check of valuation, growth, quality, and financial flexibility.
EXEL revenue
Revenue history shows whether the business has been expanding before margins and per-share metrics are considered.
Five-year revenue CAGR: 16.06%. This is endpoint-to-endpoint from the fiscal years shown — a depressed start year can inflate it, so read it against the recent bars.
Five-year revenue CAGR of 16.06% is the top-line test. A fundamental checkup becomes more durable when revenue growth is paired with earnings growth instead of depending only on margin expansion.
Top-Line Expansion and Diluted Earnings Conversion
The efficiency with which a firm translates top-line growth into shareholder value is a key indicator of operating leverage. With a five-year revenue CAGR of 16.06%, the business has demonstrated steady commercial expansion. More importantly, the five-year EPS CAGR of 51.51% indicates that net income per share has grown at a faster pace than gross sales, suggesting that the company is successfully scaling its cost structure and improving its operational efficiency over time.
EXEL EPS
EPS history shows how much of the business growth has reached shareholders.
Five-year EPS CAGR: 51.51%. This is endpoint-to-endpoint from the fiscal years shown — a depressed or negative start year can inflate it, so read it against the recent bars.
Five-year EPS CAGR of 51.51% is the shareholder conversion check. If EPS grows faster than revenue, the note should ask whether that came from margin quality, buybacks, or a temporary base effect.
Free Cash Flow Validation of GAAP Earnings
Earnings figures can sometimes be distorted by non-cash adjustments, making free cash flow the ultimate arbiter of a firm's financial health. The company's five-year free-cash-flow CAGR stands at 40.17%, confirming that cash generation has expanded significantly over the long term. This strong upward trajectory in cash flow provides solid support for the reported earnings growth, reducing the risk of aggressive accounting and demonstrating that the business possesses the self-funding capacity needed for future development.
EXEL free cash flow
Free cash flow checks whether earnings are converting into owner cash.
Five-year free-cash-flow CAGR: 40.17%. This is endpoint-to-endpoint from the fiscal years shown — a depressed or negative start year can inflate it, so read it against the recent bars.
Free-cash-flow CAGR of 40.17% is the counterweight to the EPS story. If cash flow lags earnings, the quality of the fundamental setup deserves a more cautious reading.
Profitability Thresholds and Reinvestment Efficiency
The durability of any growth story relies heavily on structural profitability and capital efficiency. Currently, the company maintains an impressive net margin of 35.33%, which indicates a highly profitable product portfolio and disciplined operating expense management. Furthermore, a return on invested capital of 37.87% demonstrates that management is deploying its resources into highly accretive projects, ensuring that newly committed capital continues to generate strong returns.
EXEL net margin
Net margin is the operating-quality check behind the growth record.
Net margin (TTM): 35.33%. The bars below are annual fiscal years.
Net margin of 35.33% shows how much revenue becomes profit. The checkup is stronger when margin quality supports EPS growth rather than simply flattering one recent period.
EXEL ROIC
ROIC tests whether the business earns enough on reinvested capital to deserve attention.
Latest ROIC: 37.87%.
ROIC of 37.87% is the reinvestment-quality check. A business with stronger returns can support a better long-term read even when the valuation is not obviously cheap.
Liquidity Profiles and Balance Sheet Safeguards
A strong operational track record can be quickly undermined by a weak balance sheet. The company exhibits exceptional financial flexibility, characterized by a current ratio of 3.46x and a highly conservative debt-to-equity ratio of 0.09x. These metrics indicate that the firm possesses ample short-term liquidity to cover obligations while maintaining a minimal debt burden, shielding the business from credit market volatility and providing a secure foundation for long-term investments.
EXEL debt-to-equity Chart
Debt-to-equity keeps the checkup honest about balance-sheet flexibility.
Latest debt-to-equity ratio: 0.09x.
Debt-to-equity of 0.09x and current ratio of 3.46x are the balance-sheet checks. They matter because growth and margins are less valuable if financial flexibility is narrowing.
Market Pricing and Implied Expectations
To understand what expectations are already priced into the stock, we look to current valuation multiples. The equity trades at a price-to-earnings ratio of 17.07x, which corresponds to an earnings yield of 5.86%. This valuation context shows the hurdle rate the business must clear to satisfy investors, representing the premium or discount the market applies to its historical growth and profitability.
EXEL Price Chart
Latest close: $54.45 as of August 28, 2026.
The close at $54.45 is not the conclusion, but it is the market reference point. The fundamental read has to explain whether growth, margins, and balance-sheet support justify the price investors are paying.
Sustained Operational Strengths and Potential Vulnerabilities
The optimistic view of the company relies on its highly profitable growth engine, where a revenue CAGR of 16.06% and an EPS CAGR of 51.51% are fully supported by an exceptional ROIC of 37.87% and a debt-free balance sheet. Conversely, the primary risk is that any future deceleration in free cash flow, which has historically grown at 40.17%, could expose the stock to multiple contraction if high reinvestment rates cannot be sustained.
Bull and bear case
Fundamental support
- Five-year revenue CAGR of 16.06% and five-year EPS CAGR of 51.51% support the business case.
- Net margin of 35.33% and ROIC of 37.87% are the quality checks behind the thesis.
Fundamental pressure
- Free-cash-flow CAGR of 40.17% can weaken the read if it falls away from EPS growth.
- Debt-to-equity of 0.09x and current ratio of 3.46x are the balance-sheet checks that can change the view.
Analytical Conclusions and Key Monitoring Points
In conclusion, the company exhibits strong fundamental alignment, with robust top-line growth, highly efficient capital allocation, and an exceptionally liquid balance sheet. This research profile would require revision if future quarterly filings show a meaningful deterioration in the five-year revenue CAGR, a drop in ROIC below historical averages, or an unexpected accumulation of leverage. This analysis serves as an objective fundamental overview and does not constitute personalized investment advice.
FAQ
What is the fundamental read on EXEL?
Exelixis, Inc. is judged through revenue growth of 16.06%, EPS growth of 51.51%, free-cash-flow growth of 40.17%, net margin of 35.33%, and ROIC of 37.87%.
Which EXEL fundamental metric matters most?
No single metric carries the article. The checkup requires growth, cash conversion, profitability quality, balance-sheet flexibility, and valuation to be read together.
When should this EXEL checkup refresh?
Its figures are as of August 28, 2026, the note's dated snapshot; a note whose figures stop verifying against reported data is corrected or unpublished.
What would change our mind
- Revenue growth moving away from the current five-year CAGR of 16.06%.
- Free-cash-flow growth drifting away from five-year EPS CAGR of 51.51%.
- ROIC or balance-sheet flexibility weakening from ROIC of 37.87% and debt-to-equity of 0.09x.
The bottom line
Exelixis, Inc. fundamental research note from TGMCharts Research, grounded in a dated fundamentals snapshot, chart exhibits, and linked source facts.
Read next: EXEL fundamentalsContinue with Exelixis, Inc.'s full stock page.How we checked this researchShowHide
Data snapshot · By TGMCharts Research.
Every number in this note comes from data we compute and store ourselves from the company's reported figures, plus verbatim excerpts from its SEC filings. When a value isn't available we say so — we never fill gaps with estimates.
Latest filing excerpt
10-Q · filed 2026-08-05 · period 2026-07-03 · SEC EDGAR source
- “We have since received notice from CMS that we qualify for the "specified small manufacturer" designation and are thereby eligible for a phase-in of the increased manufacturer discounts under the Part D Discount Program, from 2025 to 2031.”
- “In April 2026, CMS also issued a final rule on the Part D Discount Program that largely codifies the final guidance.”
Source pages
Exhibit sources
Research trail
Every number, checked
Every numeric or dated claim in this note was checked against our stored company data before publishing — each figure below links to the page it comes from.